Terms: = Ovarian cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Clinical Outcome
51 results:
1. Differences between zoledronic acid and denosumab for breast cancer treatment.
Ishikawa T
J Bone Miner Metab; 2023 May; 41(3):301-306. PubMed ID: 36879056
[TBL] [Abstract] [Full Text] [Related]
2. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and ovarian cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract] [Full Text] [Related]
3. Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with brca1 c.5096G>A (R1699Q) intermediate-risk variant.
Saito A; Tanioka M; Hirata M; Watanabe T; Odaka Y; Shimoi T; Sudo K; Noguchi E; Ishikawa M; Yonemori K
Cancer Treat Res Commun; 2022; 32():100587. PubMed ID: 35696850
[TBL] [Abstract] [Full Text] [Related]
4.
Liontos M; Zografos E; Zoumpourlis P; Andrikopoulou A; Svarna A; Fiste O; Kunadis E; Papatheodoridi AM; Kaparelou M; Koutsoukos K; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
Curr Oncol; 2021 Nov; 28(6):4446-4456. PubMed ID: 34898566
[TBL] [Abstract] [Full Text] [Related]
5. brca1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer.
Elazezy M; Prieske K; Kluwe L; Oliveira-Ferrer L; Peine S; Müller V; Woelber L; Schmalfeldt B; Pantel K; Joosse SA
Mol Oncol; 2021 Dec; 15(12):3615-3625. PubMed ID: 34601813
[TBL] [Abstract] [Full Text] [Related]
6. clinical outcome in patients with primary epithelial ovarian cancer and germline brca1/2-mutation - real life data.
Ataseven B; Tripon D; Schwameis R; Harter P; Rhiem K; Schneider S; Heikaus S; Baert T; Francesco AP; Heitz F; Traut A; Groeben HT; Schmutzler R; du Bois A
Gynecol Oncol; 2021 Dec; 163(3):569-577. PubMed ID: 34565600
[TBL] [Abstract] [Full Text] [Related]
7. Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis.
Rajan A; Nadhan R; Latha NR; Krishnan N; Warrier AV; Srinivas P
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188482. PubMed ID: 33260050
[TBL] [Abstract] [Full Text] [Related]
8. Germline and Somatic brca1/2 Gene Mutational Status and clinical outcomes in Epithelial Peritoneal, ovarian, and Fallopian Tube cancer: Over a Decade of Experience in a Single Institution in Korea.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
[TBL] [Abstract] [Full Text] [Related]
9. Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.
Matsushita H; Hasegawa K; Oda K; Yamamoto S; Asada K; Karasaki T; Yabuno A; Nishijima A; Nejo T; Kobayashi Y; Sato S; Ikeda Y; Miyai M; Takahashi Y; Yamaguchi R; Fujiwara K; Aburatani H; Kakimi K
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461346
[TBL] [Abstract] [Full Text] [Related]
10. In silico analysis of DYNLL1 expression in ovarian cancer chemoresistance.
Berkel C; Cacan E
Cell Biol Int; 2020 Aug; 44(8):1598-1605. PubMed ID: 32208526
[TBL] [Abstract] [Full Text] [Related]
11. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and brca1/2 gene mutational status.
Gallotta V; Bruno M; Conte C; Giudice MT; Davià F; Moro F; Zannoni GF; Fagotti A; De Bonis M; Capoluongo E; Scambia G; Ferrandina G
Eur J Surg Oncol; 2020 Jul; 46(7):1327-1333. PubMed ID: 32085925
[TBL] [Abstract] [Full Text] [Related]
12. Identification of immune-enhanced molecular subtype associated with brca1 mutations, immune checkpoints and clinical outcome in ovarian carcinoma.
Zheng M; Hu Y; Gou R; Liu O; Nie X; Li X; Liu Q; Hao Y; Liu J; Lin B
J Cell Mol Med; 2020 Mar; 24(5):2819-2831. PubMed ID: 31995855
[TBL] [Abstract] [Full Text] [Related]
13. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract] [Full Text] [Related]
14. clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse.
Hollis RL; Carmichael J; Meynert AM; Churchman M; Hallas-Potts A; Rye T; MacKean M; Nussey F; Semple CA; Herrington CS; Gourley C
Am J Obstet Gynecol; 2019 Sep; 221(3):245.e1-245.e15. PubMed ID: 31055034
[TBL] [Abstract] [Full Text] [Related]
15. Inherited gynaecological cancers.
George A
Curr Opin Oncol; 2018 Sep; 30(5):317-322. PubMed ID: 30036195
[TBL] [Abstract] [Full Text] [Related]
16. Biomarker Assessment of HR Deficiency, Tumor
Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
[TBL] [Abstract] [Full Text] [Related]
17. Immunogenomic Analyses of Advanced Serous ovarian cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity.
Hao D; Liu J; Chen M; Li J; Wang L; Li X; Zhao Q; Di LJ
Clin Cancer Res; 2018 Aug; 24(15):3560-3571. PubMed ID: 29661778
[No Abstract] [Full Text] [Related]
18. Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring brca1 and BRCA2 aberrations.
Hollis RL; Meynert AM; Churchman M; Rye T; Mackean M; Nussey F; Arends MJ; Sims AH; Semple CA; Herrington CS; Gourley C
BMC Cancer; 2018 Jan; 18(1):16. PubMed ID: 29298688
[TBL] [Abstract] [Full Text] [Related]
19. Location of Mutation in
Labidi-Galy SI; Olivier T; Rodrigues M; Ferraioli D; Derbel O; Bodmer A; Petignat P; Rak B; Chopin N; Tredan O; Heudel PE; Stuckelberger S; Meeus P; Meraldi P; Viassolo V; Ayme A; Chappuis PO; Stern MH; Houdayer C; Stoppa-Lyonnet D; Buisson A; Golmard L; Bonadona V; Ray-Coquard I
Clin Cancer Res; 2018 Jan; 24(2):326-333. PubMed ID: 29084914
[No Abstract] [Full Text] [Related]
20. Genetic Versus Epigenetic brca1 Silencing Pathways: clinical Effects in Primary ovarian cancer Patients: A Study of the Tumor Bank ovarian cancer Consortium.
Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI
Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938
[TBL] [Abstract] [Full Text] [Related]
[Next]
